Skip to main content

Table 1 The comparison of demographic, clinical characteristic and laboratory results of Kawasaki disease between the two groups

From: Neurological involvement in Kawasaki disease: a retrospective study

  Group Aa Group Bb P value
Clinical characteristic
 Patients, n 80 512
 Sex, male, n(%) 46(57.5) 296(57.8) 0.526
 Age, months 33.0 ± 26.8 30.4 ± 23.4 0.437
 Fever duration on admission, days 5.5 ± 3.0 5.5 ± 2.8 0.893
 Incomplete Kawasaki disease, n(%) 34(42.5) 192(37.5) 0.390
 Kawasaki disease shock syndrome, n(%) 10(12.5) 1(0.2) <0.001*
Typical clinical manifestations
 Fever, n(%) 80(100.0) 512(100.0)
 Rash, n(%) 60(75.0) 395(77.1) 0.670
 Edema & erythema of the extremities, n(%) 46(57.5) 297(58.0) 0.863
 Bilateral bulbar conjunctival injection, n(%) 70(87.5) 464(90.6) 0.480
 Erythema of oral and pharyngeal mucosa, n(%) 72(90.0) 470(91.8) 0.524
 Cervical lymphadenopathy, n(%) 38(47.5) 220(43.1) 0.470
Treatment
 The duration of antibiotic, days 6.4 ± 2.5 4.8 ± 2.2 <0.001*
 Fever duration before IVIG, days 6.4 ± 4.0 6.3 ± 3.0 0.782
 The delayed treatment of initial IVIG (>10 days) 4(5.0) 21(4.1) 0.762
 Failure to respond to initial IVIG therapy, n(%) 22(27.5) 70(13.7) 0.003*
  Patients from Cardiology Department, n(%) 9 (11.3) 62(12.1) 0.837
  Patients from non-Cardiology Department, n(%) 13 (16.3) 8(1.6) <0.001*
 Intravenous and/or Oral steroid treatment, n(%) 13(16.3) 38(7.4) 0.016*
Cardiac complications
 Coronary artery lesions, n(%) 12(15.0) 50(9.8) 0.220
  Dilatation, n(%) 11(13.8) 45(8.8) 0.180
  Aneurysms, n(%) 1(1.3) 5(1.0) 0.821
 Valve regurgitation, n(%) 8(10.0) 32(6.3) 0.229
 Cardiac enlargement, n(%) 10(12.5) 37(7.2) 0.118
 Pericardial effusion, n(%) 4(5.0) 12(2.3) 0.253
Blood examination features
 White blood cell count, × 109/L 15.5 ± 5.8 14.3 ± 5.4 0.042*
 Neutrophil rate, % 70.3 ± 17.0 66.1 ± 14.7 0.014*
 Lymphocyte rate, % 19.6 ± 12.3 25.1 ± 12.9 <0.001*
 C-reactive proteins, mg/L 96.0 ± 53.1 79.3 ± 47.8 0.003*
 Erythrocyte sediment rate, mm/h 69.4 ± 34.1 65.1 ± 29.1 0.326
 Platelet, ×109/L 325.0 ± 117.0 343.9 ± 115.0 0.164
 Hemoglobin, g/L 104.0 ± 13.3 108.4 ± 10.9 0.001*
 Alanine transaminase, U/L 75.2 ± 83.9 67.8 ± 84.4 0.516
 Aspartate transaminase, U/L 58.9 ± 88.3 49.5 ± 57.0 0.233
 Albumin, g/L 34.4 ± 7.0 37.7 ± 5.0 <0.001*
 Total bilirubin, umol/L 10.3 ± 15.3 7.7 ± 7.9 0.026*
 Cr, umol/L 33.5 ± 14.6 28.2 ± 13.8 0.003*
 Serum sodium, mmol/L 135.3 ± 4.8 136.3 ± 7.1 0.098
  1. The data are presented as mean ± standard deviation (SD) for quantitative variables and as n/% for qualitative data as appropriate. *P < 0.05
  2. IVIG Intravenous immunoglobulin
  3. aGroup A, KD patients had neurological involvement
  4. bGroup B, KD patients had no neurological involvement